Literature DB >> 4880674

A double blind study of 1-dopa treatment in Parkinson's disease.

U K Rinne, V Sonninen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4880674     DOI: 10.1159/000113660

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  8 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

3.  Lisuride, a potent drug in the treatment of muscular rigisity in rats.

Authors:  D Loos; K Halbhübner; H Herken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

4.  Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent.

Authors:  L B Sourander; R Portin; P Mölsä; A Lahdes; U K Rinne
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

Authors:  U K Rinne; E Birket-Smith; E Dupont; E Hansen; M Hyyppä; R Marttila; B Mikkelsen; H Pakkenberg; J Presthus
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849

6.  Treatment of Parkinsonism with Laevo-dopa.

Authors:  C Mawdsley
Journal:  Br Med J       Date:  1970-02-07

Review 7.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

8.  The Story of Levodopa: A Long and Arduous Journey.

Authors:  Kalyan B Bhattacharyya
Journal:  Ann Indian Acad Neurol       Date:  2022-02-22       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.